Keyword: Teva Pharmaceutical Industries
Teva received FDA approval for a fully integrated digital rescue inhaler for patients with asthma and COPD, equipped with built-in sensors.
AbbVie streamlines management team; FDA taps Flatiron exec for oversight post; and PPD beefs up therapeutics team with new leadership.
Xenotransplantation firm eGenesis hires new R&D head; Relay adds execs to chemistry, R&D; and Navidea brings on new CMO focused on imaging.
Teva has begun a limited U.S. launch of its generic EpiPen, at the same price as Mylan’s own authorized generic launched almost two years ago.
89Bio has raised $60 million to advance a stable of small molecules and biologics acquired from Teva.
DFCI's Haining to become VP, Oncology at Merck; Pfizer poaches Quest exec to spearhead digital; and Perrigo swaps CEO for former tobacco executive.
Chris Corsico left the CMO spot at Boehringer Ingelheim to fill a new role at GlaxoSmithKline: senior vice president of development.
Laquinimod was once hailed as a blockbuster heir to Copaxone but suffered a string of late-phase failures that dragged down Teva.
The FDA approved the first generic versions of Mylan’s EpiPen and EpiPen Jr, as shortages of the autoinjectors continue.